Skip to main content

Sanofi Partners with Lonza on Biologics Manufacturing Facility

Published 3/14/2017

Sanofi and Lonza initiated a joint venture in March of 2017 to create a $285 million biologics manufacturing center in Visp, Switzerland. The strategic partnership leverages Lonza’s expertise in designing, constructing, and managing large-scale mammalian cell culture facilities with Sanofi’s strength in the discovery and launch of biologics-based treatments. Construction is expected to begin in 2017 on the initial phase of the project, with full operations commencing by 2020.